Article
TB-500 Wound Repair Research Models:
Important regulatory notice. TB-500 is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference…
This is the text in its original language.
Important regulatory notice. TB-500 is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound and appears on the WADA Prohibited List in sport. This page is a literature-context overview of the published research record on TB-500 in wound-repair models. It is not personal-use guidance.
Quick research summary. TB-500 is a synthetic peptide containing an active fragment from thymosin beta-4. The published wound-repair literature is dominated by in-vitro and rodent-model work and reports observations on cellular migration, actin biology and angiogenesis-related signalling. Large human clinical-trial data is not available, so consumer ‘speeds healing' framings sit outside the public regulatory evidence base.
What the cell-biology literature reports
Thymosin beta-4 has been studied for several decades in the context of cellular migration, actin polymerisation and angiogenesis-related gene expression. The synthetic TB-500 fragment is described as containing an active sequence from this protein. Cell-culture wound-closure assays describe protocol-defined cellular-migration endpoints over hours to days. These are biochemistry observations in cell-culture systems and do not translate one-for-one to human outcomes.
What the rodent-model literature reports
Rodent wound-repair studies report protocol-defined endpoints across one to four weeks, with the dose, route and outcome measure varying by study. Independent reviewers note that rodent-model findings have not been corroborated in published large human clinical trials.
UK regulatory and sport-testing position
TB-500 has not received UK marketing authorisation. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. TB-500 is also a WADA-banned substance and WADA-accredited laboratories run targeted assays for it.
For laboratory researchers
TB-500 is widely used as a research reference compound in cell-biology and small-animal model work. Quality requirements for any research-grade reference sample are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.
Frequently Asked Questions
Does TB-500 speed up healing in humans?
Published large human clinical-trial data is not available. The evidence base is dominated by in-vitro and rodent-model work and is not a basis for personal-use efficacy predictions.
Is TB-500 licensed in the UK?
No. TB-500 has not received MHRA, EMA or FDA marketing authorisation.
Is TB-500 banned in sport?
Yes. TB-500 appears on the WADA Prohibited List.
Research use only. The compounds referenced here are research-use-only laboratory reference compounds. Products are not for human or veterinary use. TB-500 is also banned in sport under the WADA Prohibited List.
Informational content for research. This material is educational and intended for laboratory research contexts. It is not medical advice, a prescription, a clinical protocol, or a guarantee of outcome.